Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,548 JPY | +1.88% | -0.80% | -8.16% |
Sales 2024 | 1,604B 10.19B | Sales 2025 * | 1,676B 10.64B | Capitalization | 2,776B 17.64B |
---|---|---|---|---|---|
Net income 2024 | 17.04B 108M | Net income 2025 * | 81.86B 520M | EV / Sales 2024 | 1.63 x |
Net Debt 2024 | 336B 2.13B | Net Debt 2025 * | 479B 3.05B | EV / Sales 2025 * | 1.94 x |
P/E ratio 2024 |
173
x | P/E ratio 2025 * |
33.9
x | Employees | 14,484 |
Yield 2024 |
4.26% | Yield 2025 * |
4.81% | Free-Float | 98.84% |
Latest transcript on Astellas Pharma Inc.
1 day | +1.88% | ||
1 week | -0.80% | ||
Current month | +2.28% | ||
1 month | +2.28% | ||
3 months | -7.52% | ||
6 months | -13.85% | ||
Current year | -8.16% |
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | Oct. 31 |
Kenji Yasukawa
CHM | Chairman | 64 | 86-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 21-05-31 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 17-05-31 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.47% | 19 M€ | +11.22% | ||
2.09% | 240 M€ | +17.47% | ||
2.01% | 60 M€ | +24.21% | ||
1.99% | 10 M€ | +15.87% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1,548 | +1.88% | 19,855,300 |
24-05-30 | 1,520 | -1.01% | 7,142,200 |
24-05-29 | 1,536 | -1.73% | 6,325,100 |
24-05-28 | 1,562 | -0.45% | 4,676,000 |
24-05-27 | 1,570 | +0.26% | 6,702,600 |
Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.16% | 17.39B | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- 4503 Stock